**Specifications table**TableSubject areaMedical scienceMore specific subject areaPost resuscitation careType of dataTables, figuresHow data was acquiredSurveyData formatRaw data, statistically analyzed dataExperimental factorsDoes not applyExperimental featuresThe treatment, target temperature management (TTM) with 32--34 °C (12--24 h) was conducted by the discretion of the attending physician.Data source locationJapanData accessibilityData is available in this articleRelated research articleEffect of target temperature management at 32--34 °C in cardiac arrest patients considering assessment by regional cerebral oxygen saturation: A multicenter retrospective cohort study *(in press)*

**Value of the data**•The data contain raw data and supplementary contents of our original paper, and these are important information for interpretation the results of original research.•TTM at 32--34 °C could be still effective when patients with rSO~2~ 41--60% were limited to who achieved ROSC until/on hospital arrival, excluding patients achieved ROSC after hospital arrival.•The covariates of PSM and IPW analysis were not well balanced, and the overlap plots indicate the overlap of densities of the propensity scores are low in group rSO~2~ 41--60% and group rSO~2~ ≥ 61%.•The use of TTM at 32--34 °C could be effective in patients with specific degrees of cerebral injury, but the result should be interpreted carefully.

1. Data {#s0005}
=======

We examined the effectiveness of TTM at 32--34 °C considering degrees of patients' cerebral injury and cerebral circulation assessed by regional cerebral oxygen saturation (rSO~2~). This is a secondary analysis of prospectively collected registry [@bib1], [@bib2], in which comatose patients who were transferred to 15 hospitals in Japan after out-of-hospital cardiac arrest (OHCA), and we included 431 study patients ([Table S1](#s0045)) [@bib3]. In original research article, propensity score analysis revealed that TTM at 32--34 °C decreased all-cause mortality in patients with rSO~2~ 41--60% (average treatment effect on the treated \[ATT\] by propensity score matching \[PSM\] −0.51, 95%CI −0.70 to −0.33; ATT by inverse probability of treatment weighting \[IPW\] −0.52, 95%CI −0.71 to −0.34), and increased favorable neurological outcomes in patients with rSO~2~ 41--60% (ATT by PSM 0.50, 95%CI 0.32--0.68; ATT by IPW 0.52, 95%CI 0.35--0.69). TTM at 32--34 °C could be effective to decrease all-cause mortality in comatose OHCA patients with rSO~2~ 41--60% on hospital arrival. [Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"} show that the covariates of PSM and IPW analysis were not well balanced. The overlap plots ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}) show the overlap of densities of the propensity scores are low in group rSO~2~ 41--60% and group rSO~2~ ≥ 61%, this indicates the overlap assumption on the treatment effect on the potential-outcome models may be violated. [Table 5](#t0025){ref-type="table"} shows that TTM could be still effective when patients with rSO~2~ 41--60% were limited to who achieved ROSC until/on hospital arrival, excluding patients achieved ROSC after hospital arrival.Fig. 1Overlap plots of propensity score matching analysis and inverse probability of treatment weighting for all-cause mortality.Fig. 1Fig. 2Overlap plots of propensity score matching analysis and inverse probability of treatment weighting for favorable neurological outcomes.Fig. 2Table 1Balance of covariates of propensity score matching analysis for all-cause mortality[a](#tbl1fna){ref-type="table-fn"}.Table 1**CovariatesrSO**~**2**~**≥ 61%, G1 (*N* = 68, 34 pairs)rSO**~**2**~**41--60%, G2 (*N* = 67, 31 pairs)rSO**~**2**~**15--40%, G3 (N=296, 54 pairs)SDVariance ratioSDVariance ratioSDVariance ratioBefore matchingAfter matchingBefore matchingAfter matchingBefore matchingAfter matchingBefore matchingAfter matchingBefore matchingAfter matchingBefore matchingAfter matching**Sex0.36−0.370.652.630.251.090.821.00.280.0400.860.97Age0.38−0.140.832.25−1.520.112.470.99−0.18−0.220.690.77Location of cardiac arrest0.37−0.161.041.660.71−0.401.590.780.41−0.0741.230.97Witness0.092−0.580.84--0.13−0.350.872.000.44−0.140.681.29Type of bystander-witness status0.14−0.371.093.250.250.461.132.970.37−0.170.950.97Bystander-initiated CPR0.15−0.631.0041.380.22−0.471.041.300.27−0.111.140.996Initially documented rhythms on the scene of cardiac arrest−0.400.0241.731.100.320.0734.7624.31−0.72−0.361.270.83                          Pre-hospital procedures Advanced airway device0.150.701.0041.52-0.770.0661.271.04-0.17-0.111.091.04Intravenous epinephrine administration0.210.470.842.42-0.95-0.210.780.80-0.33-0.340.700.68Defibrillation1.650.00.981.01.271.278.268.000.520.262.471.38ROSC until/on hospital arrival0.46-0.510.49--0.521.090.700.850.360.173.121.50Emergency call to hospital arrival-0.56-0.360.120.097-0.0590.293.759.44-0.45-0.570.380.39rSO~2~ at hospital arrival-0.51-0.0510.521.720.210.0710.701.370.390.281.431.26Rhythms at rSO~2~ measurement0.50-0.450.39--0.341.031.020.93-0.32-0.202.161.50                          Procedures after hospital arrival Coronary angiography1.14-0.191.471.220.981.104.237.930.940.995.456.77 Primary percutaneous coronary intervention-0.098-1.690.810.580.600.755.78--0.490.397.593.54[^1][^2]Table 2Balance of covariates of propensity score matching analysis for favorable neurological outcomes[a](#tbl2fna){ref-type="table-fn"}.Table 2**CovariatesrSO**~**2**~**≥61%, G1 (*N* = 68, 34 pairs)rSO**~**2**~**41--60%, G2 (*N* = 67, 31 pairs)rSO**~**2**~**15--40%, G3 (N=296, 54 pairs)SDVariance ratioSDVariance ratioSDVariance ratioBefore matchingAfter matchingBefore matchingAfter matchingBefore matchingAfter matchingBefore matchingAfter matchingBefore matchingAfter matchingBefore matchingAfter matching**Sex0.36−0.370.652.630.251.090.821.000.280.0400.860.97Age−0.38−0.140.832.251.520.112.470.99−0.18−0.220.690.77Location of cardiac arrest0.37−0.161.041.660.71−0.401.590.780.041−0.0741.230.97Witness0.092−0.580.84--0.13−0.350.872.000.44−0.140.681.29Type of bystander-witness status0.14−0.371.093.250.250.461.132.970.37−0.170.950.97Bystander-initiated CPR−0.15−0.631.0041.380.22-0.471.041.300.27−0.111.140.996Initially documented rhythms on the scene of cardiac arrest−0.400.0241.731.100.320.0734.7624.31−0.72−0.361.270.83                          Pre-hospital procedures Advanced airway devices0.150.701.0041.52−0.770.0661.271.04−0.17−0.111.091.04 Intravenous epinephrine administration−0.210.470.842.42−0.95−0.210.780.80−0.33−0.340.700.68 Defibrillation1.650.00.981.001.271.278.268.000.520.262.471.38ROSC until/on hospital arrival0.46−0.510.49--0.521.090.700.850.360.173.111.50Emergency call to hospital arrival−0.56−0.360.120.097−0.0590.293.759.44−0.45−0.570.380.39rSO~2~ at hospital arrival0.51−0.0510.521.720.210.0710.701.370.390.281.431.26Rhythms at rSO~2~ measurement0.50−0.450.39--0.341.031.020.93−0.32−0.202.161.50                          Procedures after hospital arrivalCoronary angiography1.14−0.191.471.220.981.104.237.930.940.995.456.77Primary percutaneous coronary intervention−0.098−1.690.810.580.600.755.78--0.490.397.593.54[^3][^4]Table 3Balance of covariates of inverse probability of treatment weighting for all-cause mortality[a](#tbl3fna){ref-type="table-fn"}.Table 3**CovariatesrSO2 ≥ 61%, G1 (*N* = 45)rSO2 41--60%, G2 (*N* = 42)rSO2 15--40%, G3 (*N* = 228)SDVariance ratioSDVariance ratioSDVariance ratioBefore weightedAfter weightedBefore weightedAfter weightedBefore weightedAfter weightedBefore weightedAfter weightedBefore weightedAfter weightedBefore weightedAfter weighted**Sex0.360.0620.650.900.250.0750.821.0010.28−0.0610.861.02Age−0.380.0690.831.06−1.520.172.470.86−0.18−0.140.690.86Location of cardiac arrest0.37−0.0451.041.480.71−0.291.590.750.410.211.231.14Witness0.092−0.100.841.270.13−0.540.871.500.440.130.680.92Type of bystander-witness status0.14−0.171.091.430.25−0.0491.131.700.370.0760.950.89Bystander-initiated CPR−0.15−0.541.0041.160.22−0.471.040.940.270.0801.141.04Initially documented rhythms on the scene of cardiac arrest−0.400.241.731.14−0.320.174.764.43−0.72−0.441.270.79                          Pre-hospital procedures Advanced airway devices0.150.771.0041.24−0.77−0.451.270.810.17−0.0601.091.03 Intravenous epinephrine administration−0.210.210.841.31−0.95−0.590.780.580.33−0.330.700.68 Defibrillation1.650.440.980.821.270.768.266.930.520.262.471.62ROSC at hospital arrival0.460.0930.490.850.520.350.701.090.360.000843.121.003Emergency call to hospital arrival0.56−0.370.120.059−0.0590.000623.752.330.45−0.430.380.36rSO~2~ at hospital arrival0.51−0.380.520.690.21−0.0820.700.660.390.341.431.22Rhythms at rSO~2~ measurement0.500.200.390.540.340.611.020.70−0.32−0.392.161.21                          Procedures after hospital arrival Coronary angiography1.140.111.470.990.980.644.234.920.940.785.454.13 Primary percutaneous coronary intervention−0.098−1.020.810.270.600.425.786.730.490.447.595.01[^5][^6]Table 4Balance of covariates of inverse probability of treatment weighting for favorable neurological outcomes[a](#tbl4fna){ref-type="table-fn"}.Table 4**CovariatesrSO2 ≥61%, G1 (*N* = 68)rSO2 41--60%, G2 (*N* = 67)rSO2 15--40%, G3 (*N* = 296)SDVariance ratioSDVariance ratioSDVariance ratioBefore weightedAfter weightedBefore weightedAfter weightedBefore weightedAfter weightedBefore weightedAfter weightedBefore weightedAfter weightedBefore weightedAfter weighted**Sex0.360.0620.650.900.250.320.820.970.280.0360.860.99Age−0.380.0690.831.061.52−0.00512.470.77−0.18−0.280.690.63Location of cardiac arrest0.37−0.0451.041.480.710.0921.590.760.410.111.231.21Witness0.092−0.100.841.270.13−0.220.871.320.440.0220.680.99Type of bystander-witness status0.14−0.171.091.430.250.171.131.490.37-0.0740.950.77Bystander-initiated CPR−0.15−0.541.0041.160.22−0.321.040.990.270.00721.141.004Initially documented rhythms on the scene of cardiac arrest0.400.241.731.14−0.320.254.764.85−0.72−0.751.270.59                          Pre-hospital procedures Advanced airway devices0.150.771.0041.24−0.77−0.351.270.96−0.17−0.431.091.05 Intravenous epinephrine administration−0.210.210.841.31−0.95−0.760.780.53−0.33−0.370.700.64 Defibrillation1.650.440.980.821.270.778.266.850.520.0642.471.16ROSC at hospital arrival0.460.0930.490.850.520.160.701.030.360.0593.121.25Emergency call to hospital arrival0.56−0.370.120.0590.059−0.0823.732.670.45−0.280.380.44rSO~2~ at hospital arrival−0.51−0.380.520.690.210.000.700.810.390.0861.431.10Rhythms at rSO~2~ measurement0.500.200.390.540.340.181.021.040.32−0.262.161.23                          Procedures after hospital arrival Coronary angiography1.140.111.470.990.980.564.234.000.940.515.453.87 Primary percutaneous coronary intervention−0.098−1.020.810.270.600.405.786.320.490.217.592.87[^7][^8]Table 5Analysis results on the effectiveness of target temperature management (32--34 °C) for all-cause mortality or favorable neurological outcomes of patients those who achieved return of spontaneous circulation until/on hospital arrival (*n* = 117).Table 5**Effectiveness of TTM (32--34℃) on all-cause mortalityEffectiveness of TTM (32--34℃) on favorable outcomes (CPC 1--2)rSO**~**2**~**≥61%, G1 (n=54)rSO**~**2**~**41--60%, G2 (n=43)rSO**~**2**~**15--40%, G3 (n=20)rSO**~**2**~**≥61%, G1 (n=54)rSO**~**2**~**41--60%, G2 (n=43)rSO**~**2**~**15--40%, G3 (n=20)Univariate analysis** **Risk ratio**0.290.360.701.8711.521.22 **\[95%CI\]**\[0.11 to 0.80\]\[0.20 to 0.65\]\[0.30 to 1.64\]\[1.06 to 3.29\]\[1.68 to 79.15\]\[0.32 to 4.65\] **Risk difference**0.33-0.57-0.190.330.580.061 **\[95%CI\]**\[-0.56 to -0.091\]\[-0.80 to -0.34\]\[-0.62 to 0.24\]\[0.071 to 0.58\]\[0.37 to 0.80\]\[-0.34 to 0.47\]              **Multivariate logistic regression**[a](#tbl5fna){ref-type="table-fn"} **Odds ratio**0.360.164.65e-061.3322.631.25 **\[95%CI\]**\[0.040 to 3.25\]\[0.0061 to 4.33\]\[5.11e-14 to 423.43\]\[0.25 to 7.11\]\[0.50 to 1016.29\]\[0.13 to 12.47\]              **Propensity-score matching**[b](#tbl5fnb){ref-type="table-fn"} **ATE**-0.074-0.63-0.150.0740.630.050 **\[95%CI\]**\[-0.42 to 0.27\]\[-0.86 to -0.40\]\[-0.66 to 0.36\]\[-0.012 to 0.16\]\[0.40 to 0.86\]\[-0.22 to 0.32\] **ATT**0.033-0.68-0.44-0.0670.640.22 **\[95%CI\]**\[-0.17 to 0.24\]\[-0.86 to -0.50\]\[-0.74 to -0.14\]\[-0.33 to 0.20\]\[0.46 to 0.82\]\[-0.19 to 0.64\]              **IPW**[b](#tbl5fnb){ref-type="table-fn"} **ATE**-0.051-0.52-0.290.0610.530.045 **\[95%CI\]**\[-0.30 to 0.19\]\[-0.78 to -0.26\]\[-0.55 to -0.038\]\[-0.19 to 0.31\]\[0.28 to 0.78\]\[-0.29 to 0.38\] **ATT**0.034-0.64-0.42-0.0980.610.22 **\[95%CI\]**\[-0.18 to 0.25\]\[-0.84 to -0.44\]\[-0.72 to -0.12\]\[-0.37 to 0.18\]\[0.40 to 0.81\]\[-0.18 to 0.62\][^9][^10][^11]

2. Experimental design, materials, and methods {#s0010}
==============================================

2.1. Study design and data source {#s0015}
---------------------------------

The original research article is a secondary analysis of prospectively collected registry, the Japan-Prediction of Neurological Outcomes in Patients Post-cardiac Arrest Registry \[UMIN trial ID 000005065\] [@bib2], [@bib3], in which OHCA patients transported to 15 tertiary emergency hospitals in Japan from May 2011 to August 2013 were consecutively registered. The database consists of pre-hospital and in-hospital data collected from the Japanese emergency medical service (EMS) system and medical charts of each hospital by using the Utstein style [@bib4].

2.2. Study population {#s0020}
---------------------

Comatose patients after OHCA were included in this study if they achieved ROSC. Exclusion criteria were trauma, accidental hypothermia, age \<18 years, completion of "Do Not Resuscitate [@bib5]" orders, and a Glasgow coma scale (GCS) score of \>8 on arrival at the hospital.

After arriving at hospital, two disposable probes of NIRS (INVOS TM 5100C, Covidien, Boulder, CO, USA) were attached to the patient\'s forehead. rSO~2~ was monitored at least for 1 minute with the probes after several seconds of stable monitoring, and the lowest rSO~2~ value was used.

Patients were stratified into three groups according to the recorded rSO~2~: group rSO~2~ ≥61% (G1), group rSO~2~ 41--60% (G2), and group rSO~2~ ≤40% (G3), by referring to previous studies which suggest that values less than 35--40% or an absolute decrease of 20% from baseline should alert clinicians to perform appropriate interventions to reverse potential cerebral hypoxemia [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], and reported that rSO~2~ values are 60% or higher in most stable patients [@bib7], [@bib9], [@bib11].

2.3. Variables {#s0025}
--------------

### 2.3.1. Treatment and outcome measurement {#s0030}

The treatment, TTM with 32 to 34°C (12--24 h) was conducted by the discretion of the attending physician.

We defined the primary outcome as all-cause mortality at 90 days after cardiac arrest, and the secondary outcome as favorable neurological outcome evaluated according to the Cerebral Performance Category (CPC) [@bib12]. The CPC is a 5-point scale ranging from 1 (good cerebral performance) to 5 (dead). We defined favorable neurological outcome as a CPC 1 or 2 by reference to the international guidelines [@bib13], [@bib14]. Both all-cause mortality and neurological outcome are core elements in the guidelines. In principle, CPC in individual patients were determined by the physician-in-charge, but in cases of missing data, the main researcher who developed the database determined CPC by contacting patients or family members; both were blinded to rSO~2~ readings.

### 2.3.2. Covariates {#s0035}

We used patient characteristics as covariates, including demographic characteristics (sex, age), pre-hospital status (location of arrest, witnessed arrest, bystander CPR, first monitored rhythm), pre-hospital resuscitation attempts by EMS (airway management by intubation or laryngeal mask airway device, intravenous injection of adrenaline, usage of Automated External Defibrillator \[AED\]), patient status at emergency unit (time from emergency call to hospital arrival, rhythm of electrocardiogram on rSO~2~ measurement), cardiac origin or not (presumed by attending physician retrospectively), and procedures after hospitalization (ECPR, coronary angiography, primary percutaneous coronary intervention).

2.4. Statistical analyses {#s0040}
-------------------------

In original research article, effectiveness of TTM was evaluated by group according to rSO~2~. Risk ratios and risk differences were obtained by univariate analyses. In multivariate logistic analysis, explanatory variables including sex, age, witnessed arrest, PaO2, PaCO2, first monitored rhythm (shockable \[VF/pulseless VT\] / non-shockable \[PEA, asystole, unknown\]) were used for statistical adjustment. Treatment effect estimation was also performed by propensity-score matching (PSM) and inverse-probability weighting (IPW), in order to adjust for differences in baseline characteristics [@bib15], [@bib16], [@bib17], [@bib18]. All analyses were performed with Stata SE, version 14.0 (Stata Corp., College Station, TX, USA). Tests of statistical significance were two-tailed with an alpha of 0.05.

Potential-outcome models, also known as Rubin causal models, were used to estimate the distribution of individual-level treatment effects, i.e., changes in outcome caused by receiving one treatment over another [@bib17], [@bib18]. We used the average treatment effect (ATE: average effect of the treatment in the population) and average treatment effect on the treated (ATT: average treatment effect among those who received the treatment).

In PSM analysis, we performed nearest neighbor matching within caliper [@bib16]. We basically used age, sex, witnessed arrest, PaO2, PaCO2 and first monitored rhythm (shockable / non-shockable) as covariates for estimating the propensity score (PS), and if possible, more variables relating to patient characteristics observed before TTM were also used to increase the accuracy of the PS model. We used calipers of width 0.2\*(SD of log PS) for matching and also included interaction and higher order terms. In IPW analysis, we basically used same covariates as PSM, and if possible, more variables observed before TTM were used, including interaction and higher order terms. We showed balances of covariates ([Table 1](#t0005){ref-type="table"}, [Table 2](#t0010){ref-type="table"}, [Table 3](#t0015){ref-type="table"}, [Table 4](#t0020){ref-type="table"}) and overlap plots ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}) of PSM and IPW analysis. Sensitivity analyses were performed by limiting patients to those who achieved ROSC upon hospitals arrival (excluding patients with ROSC after arrival) ([Table 5](#t0025){ref-type="table"}).

Appendix A. Supplementary material {#s0050}
==================================

Supplementary material.
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Supplementary data associated with this article can be found in the online version at [10.1016/j.dib.2018.02.050](http://dx.doi.org/10.1016/j.dib.2018.02.050){#ir0010s}.

[^1]: SD=standard deviation, CPR=cardiopulmonary resuscitation, ROSC=return of spontaneous circulation.

[^2]: SDs and variance ratios are results from estimating average treatment effects on the treated (ATT).

[^3]: SD=standard deviation, CPR=cardiopulmonary resuscitation, ROSC=return of spontaneous circulation.

[^4]: SDs and variance ratios are results from estimating average treatment effects on the treated (ATT).

[^5]: SD = standard deviation, CPR = cardiopulmonary resuscitation, ROSC = return of spontaneous circulation.

[^6]: SDs and variance ratios are results from estimating average treatment effects (ATE).

[^7]: SD=standard deviation, CPR=cardiopulmonary resuscitation, ROSC=return of spontaneous circulation.

[^8]: SDs and variance ratios are results from estimating average treatment effects (ATE).

[^9]: TTM=target temperature management, CPC=cerebral performance category, ATE=average treatment effect, ATT=average treatment effect on the treated, IPW=inverse probability of treatment weighting.

[^10]: In multivariate logistic analysis, explanatory variables including sex, age, witnessed arrest, PaO2, PaCO2, first monitored rhythm (shockable \[VF/pulseless VT\]/non-shockable \[PEA, asystole, unknown\]) were used for statistical adjustment.

[^11]: We used age, sex, witnessed arrest, PaO2, PaCO2, first monitored rhythm (shockable \[VF/pulseless VT\] / non-shockable \[PEA, asystole, unknown\]) as covariates for estimating the PS, and if possible, more variables relating to patient characteristics observed before TTM were also used.
